NASDAQ: SXTP60 Degrees Pharmaceuticals Inc Stock
$0.23+0.01 (+4.55%)
Updated May 17, 2024
SXTP Price
$0.23
Fair Value Price
$0.33
Market Cap
$2.73M
52 Week Low
$0.20
52 Week High
$8.65
P/E
-0.22x
P/B
0.38x
P/S
4.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$569.86k
Earnings
-$735.17k
Gross Margin
-19.5%
Operating Margin
72.24%
Profit Margin
-178%
Debt to Equity
0.17
Operating Cash Flow
-$5M
Beta
-0.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SXTP Overview
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SXTP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SXTP ($0.23) is undervalued by 31.39% relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SXTP ($0.23) is significantly undervalued by 31.39% relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SXTP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SXTP due diligence checks available for Premium users.
Be the first to know about important SXTP news, forecast changes, insider trades & much more!
SXTP News
Valuation
SXTP fair value
Fair Value of SXTP stock based on Discounted Cash Flow (DCF)
Price
$0.23
Fair Value
$0.33
Undervalued by
29.86%
SXTP ($0.23) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SXTP ($0.23) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SXTP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SXTP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
8.47x
Market
30.97x
SXTP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
6.01x
SXTP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SXTP's financial health
Profit margin
Revenue
$80.7k
Net Income
$430.5k
Profit Margin
382.7%
SXTP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SXTP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.4M
Liabilities
$1.3M
Debt to equity
0.17
SXTP's short-term assets ($7.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SXTP's short-term assets ($7.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SXTP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
-$9.8k
Financing
$1.9M
SXTP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SXTP vs Biotech Stocks
60 Degrees Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.